Author: PharmaSignal News Desk

GSK CEO transition sees Emma Walmsley stepping down, with Luke Miels set to take over on 1 January 2026.

Cipla Q1 earnings beat forecast, leading to a 5% share increase on 10 September 2025.

FDA warning letters target misleading advertising by Novo Nordisk, Eli Lilly, and Hims, urging improved transparency and compliance.

Pfizer Metsera acquisition enhances its obesity drug portfolio with promising GLP-1 and amylin candidates for $4.9 billion.

FDA approves Forzinity for Barth syndrome, affecting 150 people in the U.S., after months of regulatory uncertainty.

Successful drug launches face challenges like market timing and product advantage. Learn how to overcome these with insights from Jason O’Neill.

FDA warning letters target misleading drug ads, raising concerns about agency’s staffing for enforcement.

GSK $30B investment aims to expand US manufacturing, countering global pricing challenges.

Biogen Alcyone acquisition grants access to implantable device, potentially easing RNA drug delivery for treatments like Spinraza.

Arvinas out-license vepdegestrant with Pfizer, impacting their partnership and market strategy.